The nanoparticle MRI contrast agent Ferrotran®, newly developed by SPL Medical, offers patients with lymph node metastases from prostate cancer a significantly better prognosis. The sooner affected lymph nodes are discovered, the better the chances of recovery with targeted, less invasive treatment. Ferrotran® uses iron oxide nanoparticles to make metastases as small as 2 mm visible, thus making life-saving therapies possible at a significantly earlier point in time.